{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Among 7 patients, no one progressed during neoadjuvant cetuximab per RECIST 1.1 CT criteria (0%).","groups":[{"description":"Patients receive cetuximab IV over 60-120 minutes for 3 weeks. Patients then undergo EBRT over 6-7 weeks. Patients achieving response continue weekly doses of cetuximab until radiation therapy is completed. Patients unable to achieve response or progression receive cisplatin IV over 1-2 hours on days 1, 22, and 43 of radiation therapy.\n\ncetuximab: Given IV\n\ncisplatin: Given IV\n\nexternal beam radiation therapy: Undergo EBRT\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Cetuximab, Cisplatin, EBRT)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"This measure what not evaluated because the study was halted prematurely due to low accrual.","reportingStatus":"POSTED","timeFrame":"Day 14-21 after the first dose of cetuximab","title":"Percent of Patients Who Progress During Neoadjuvant Cetuximab by CT RECIST 1.1 Criteria","type":"SECONDARY","unitOfMeasure":"Participants"}